




RealRate

PHARMACEUTICAL 2013

Lixte Biotechnology Holdings INC
Rank 153 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Net Income, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 80% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	1,753
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	261
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,474
Other Liabilities	0
Other Net Income	0.0080
Other Revenues	0
Property and Equipment	0
Research and Development	1,012
Selling, General and Administrative Expense	1,094

Output Variable	Value in 1000 USD
Assets	1,753
Liabilities	261
Expenses	3,579
Revenues	0
Stockholders Equity	1,492
Net Income	-3,579
Comprehensive Net Income	-3,579
BaseVar	2,797
ECR before LimitedLiability	-32%
Economic Capital Ratio	140%